Self-injection of Adalimumab in Adult Japanese Subjects With Rheumatoid Arthritis

A Non-Randomized, Open-Label, Roll-Over Study With Self Injection of Adalimumab in Adult Japanese Subjects With Rheumatoid Arthritis

The purpose of this study is to evaluate the long-term safety of subcutaneous (SC) self-injections (by the subject or subject's family member) of adalimumab in adult Japanese subjects with Rheumatoid Arthritis in an open-label study.

Inclusion Criteria:

• Completed Week 36 of Study M03-651 [NCT 00235872]
• Wish to participate in self-injection study
• Give written informed consent
• Comply with protocol requirements

Exclusion Criteria:

• Subject develops serious adverse events at time of eligibility confirmation
• Subject develops severe infections requiring hospitalization or IV injection of antibiotics within 28 days before eligibility confirmation
• Subject develops infections requiring oral administration of antibiotics within 14 days before eligibility confirmation
• The investigator considers the subject inappropriate for participation